Objetivo: determinar la relación entre la obesidad abdominal y los principales factores de riesgo cardiovascular en una población aparentemente sana.
Material y métodos: estudio transversal comparativo al que se incluyeron 186 individuos aparentemente sanos, hombres y mujeres no embarazadas mayores de 18 años, habitantes de la ciudad de México. Se llevó a cabo historia médica detallada y exploración física completa para colectar información sobre las variables antropométricas y de laboratorio. La obesidad abdominal se definió por un perímetro de cintura ≥ 80 cm en la mujer y ≥ 90 cm en el hombre.
Resultados: se integraron 125 mujeres (67.2 %) y 61 hombres (32.8 %); 151 sujetos (81.2 %) presentaron resistencia a la insulina y 130 (69.9 %), obesidad abdominal; de estos últimos, 96 (46.2 %) presentaron síndrome metabólico. Se encontró elevada prevalencia de hipertrigliceridemia (31 %) y niveles bajos de HDL-colesterol (58 %) en la población sin obesidad abdominal.
Conclusiones: aun cuando identifica a una elevada proporción de sujetos con factores de riesgo cardiovascular, el punto de corte utilizado para definir obesidad abdominal no reconoció una importante proporción de individuos con alteraciones en el perfil de lípidos.
Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, et al. Obesity, a worldwide epidemic related to heart disease and stroke. Group III: worldwide comorbidities of obesity. Circulation 2004; 110:476-483.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its com-plications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabetic Med 1998; 15:539-553.
Balkau B, Charles MA, the European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16:442-443.
Executive summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome a new worldwide definition. Lancet 2005; 366:1059-1062.
Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent to sex in black NIDDM subjects. Am J Physiol 1997; 273:425-432.
Lebovitz HE. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 2005; 28:2322-2325.
Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45:633-638.
Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hipertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small dense LDL) in men. Circulation 2000; 102:179-184.
Danadian K, Balasekaran G, Lewy V, Meza MP, Robertson R, Arslanian SA. Insulin sensitivity in African-American children with and without family history of type 2 diabetes. Diabetes Care 1999; 22:1325-1329.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28(Suppl 1):S37-S42.
Warnik GR, Alberts JJ. Heparin-Mn2 + quantitation of high density lipoprotein cholesterol: an ultra filtration procedure for lipemic samples. J Clin Chem Biochem 1978; 24:900.904.
Friedewald WT, Kevy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use the preparative ultracentrifuge. J Clin Chem Biochem 1972; 18:499-502.
Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in African. American children: decreased insulin clearance and increased insulin secretion and its relationship to sensitivity. Diabetes 2002; 51:3014-3019.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin con-centrations in man. Diabetologia 1985; 28:412-419.
Sánchez-Castillo CP, Velásquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James PT. Anthro-pometric cutoff points for predicting chronic disease in the Mexican National Health Survey 2000. Obes Res 2003; 11:442-451.
Reaven G. The metabolic syndrome: requiescat in pace. Clin Chem 2005; 51:1-7.
St-Onge MP, Jansssen I. Metabolic syndrome in normal-weight Americans. Diabetes Care 2004; 27:2222-2228.
Guerrero-Romero F, Rodríguez-Morán M. Pre-valence of dyslipidemia in non-obese prepubertal children and its association with family history of diabetes, high blood pressure, and obesity. Arch Med Res 2006; 37:1015-1021.
Aguilar-Salinas C, Rojas R, Pérez-Gómez F. El síndrome metabólico: un concepto en evolución. Gac Med Mex 2004; 140(Supl 2):S41-S48.
Pankow JS. Insulin resistance and cardiovascular disease risk factors in children of parent with the insulin Resistance (metabolic) Syndrome. Diabetes Care 2004; 27:775-780.
Grundy SM. Definition of metabolic syndrome. Circulation 2004; 109:433-438.